Pharmafile Logo
Pharmafocus logo
Advanced Search

Oxford BioMedica’s lung cancer candidate shows promise

October 25, 2005
Research and Development

A promising antibody developed by UK-based Oxford BioMedica is poised to enter clinical trials to treat lung cancer.The 5T4 antibody-targeted …

News

Pharma continues to invest in UK research and development

October 24, 2005
Sales and Marketing Pfizer, R&D

 UK pharma and biotech companies increased R&D investment by 4% in the last year, according to the latest government figures.The …

News

Blockbuster partnerships

October 21, 2005
Research and Development

Since pharma'ps big wave of innovation during the early 1990s, peaking in 1996 when 131 new drug applications were filed …

Feature

Vaccine companies to compete for UK pandemic contract

October 20, 2005
Sales and Marketing

Vaccine companies are to compete with each other to produce a vaccine against a potential pandemic flu – although no-one …

News

New approvals in TNF-blocker class

October 20, 2005
Sales and Marketing

Competition in one of the industry's fastest growing markets is intensifying with new approvals for two TNF-blocker drugs.Schering-Plough and Centocor's …

News

Resolute wins PR Consultancy of the Year award

October 20, 2005
Medical Communications

Healthcare agency Resolute Communications has been named consultancy of the year at the PRWeek awards, believed to be the first …

News

Once a day pill promises period-free contraception

October 20, 2005
Sales and Marketing

The world's first-ever contraceptive pill to offer women complete freedom from menstruation could be launched by next year.Wyeth's Lybrel is …

News

Tarceva/Avastin combination disappoints in kidney cancer

October 19, 2005
Sales and Marketing

Early results from trials suggest adding Tarceva to Avastin has no extra benefit in the treatment of kidney cancer.Researchers at …

News

Pharma – partners of NHS choice?

October 19, 2005

The government sees choice as a major driver for promoting quality, responsiveness, efficiency and equity in public services. Choice in …

Feature

Merck to co-develop novel prostate cancer candidate

October 18, 2005
Research and Development

Merck is to develop a new monoclonal antibody which has shown promise in treating prostate cancer.The US company has signed …

News

Exubera recommended by European regulator

October 18, 2005
Sales and Marketing

Exubera, the first ever inhaled insulin product is set for approval in Europe following a key regulatory recommendation.The positive opinion …

News

Winning CROs look east for expansion

October 18, 2005
Research and Development

The new onus on outsourcing has seen CROs reap the benefits of an industry striving to cut resource investment while …

Feature

Pharma increases vaccine production as bird flu hits Europe

October 14, 2005
Manufacturing and Production

Pharmaceutical companies are being urged to step up vaccine production as the strain of bird flu that killed 59 people …

News

Pfizer wins UK Lipitor court battle

October 14, 2005
Sales and Marketing

Pfizer has won an important legal battle to maintain its UK patent on best-selling cholesterol drug Lipitor.The UK High Court …

News

Sanofi-Aventis launch new short-acting insulin competitor Apidra

October 13, 2005
Sales and Marketing

Apidra, a new short-acting insulin analogue, has been launched in the UK by Sanofi-Aventis.Short-acting analogues have a faster onset of …

News

EMEA reforms to speed drug approval

October 13, 2005
Sales and Marketing

Europe's medicines regulator is looking to communicate more effectively with pharma companies as part of a drive to accelerate drug …

News

Merck looks to rebuild reputation one year on from Vioxx

October 13, 2005
Sales and Marketing

Merck looks set to launch a new public relations campaign across Europe in an attempt to repair damage done to …

News

Unions vote against NHS ‘privatisation’

October 13, 2005

The government lost the vote at its party conference on expanding the role of the private sector in the NHS.A …

News

VNU shareholders rebel over IMS bid

October 13, 2005
Sales and Marketing

A significant minority of shareholders in VNU are against its planned $7 billion acquisition of pharmaceutical information company IMS Health.The …

News

Reducing POM to P headaches

October 12, 2005
Sales and Marketing

Following an eight-week period of public consultation, the Committee on Safety of Medicines is to shortly advise health ministers about …

Feature
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026